Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes

ClinicalTrials.gov ID: NCT02825251

Public ClinicalTrials.gov record NCT02825251. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 8:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT02825251
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
472 participants

Conditions and interventions

Interventions

  • Faster-acting insulin aspart Drug
  • insulin aspart Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 5, 2016
Primary completion
Jun 19, 2017
Completion
Jul 20, 2017
Last update posted
Nov 20, 2019

2016 – 2017

United States locations

U.S. sites
30
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
Novo Nordisk Investigational Site Encino California 91436
Novo Nordisk Investigational Site Fresno California 93720
Novo Nordisk Investigational Site Roseville California 95661
Novo Nordisk Investigational Site San Mateo California 94401
Novo Nordisk Investigational Site San Ramon California 94583
Novo Nordisk Investigational Site Santa Barbara California 93105
Novo Nordisk Investigational Site Walnut Creek California 94598
Novo Nordisk Investigational Site Newark Delaware 19713
Novo Nordisk Investigational Site Atlanta Georgia 30339
Novo Nordisk Investigational Site Idaho Falls Idaho 83404-7596
Novo Nordisk Investigational Site Arlington Heights Illinois 60005-4144
Novo Nordisk Investigational Site Lexington Kentucky 40503
Novo Nordisk Investigational Site Rockville Maryland 20852
Novo Nordisk Investigational Site Boston Massachusetts 02215
Novo Nordisk Investigational Site Minneapolis Minnesota 55416
Novo Nordisk Investigational Site Las Vegas Nevada 89148
Novo Nordisk Investigational Site Nashua New Hampshire 03063
Novo Nordisk Investigational Site Albany New York 12206
Novo Nordisk Investigational Site Asheville North Carolina 28803
Novo Nordisk Investigational Site Chapel Hill North Carolina 27517
Novo Nordisk Investigational Site Pittsburgh Pennsylvania 15224-2215
Novo Nordisk Investigational Site Chattanooga Tennessee 37404-1192
Novo Nordisk Investigational Site Chattanooga Tennessee 37411
Novo Nordisk Investigational Site Amarillo Texas 79106
Novo Nordisk Investigational Site Austin Texas 78749
Novo Nordisk Investigational Site Dallas Texas 75231
Novo Nordisk Investigational Site Dallas Texas 75246
Novo Nordisk Investigational Site Mesquite Texas 75149
Novo Nordisk Investigational Site Federal Way Washington 98003
Novo Nordisk Investigational Site Renton Washington 98057

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 62 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02825251, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 20, 2019 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02825251 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →